Agree frrol. Lpc is to fund the AD ph2/3. Assuming the Biogen testing is positive, which I believe is positive after reading the abstract for the September medical conference in which the subject is about moving from preclinical to clinical trials - mentioning MS along with PD and Rett, if Biogen and Anavex partner on MS, I guarantee the rest of the indications and pipeline are being negotiated. I think that's exactly what happened here. I think Biogen will end up marketing and distributing 2-73 and 3-71. If Anavex, using Adaptive trial designs can design a ph2/3 which they can fund through LPC financing, why would they partner for the ph2/3? Makes no sense. I think the positive and encouraging results to date were a surprise. I think the strong signal allowed a smaller patient population for the next trial which made it a reality they could go it alone. I don't think they planned for these types of results. I'd bet Biogen is playing hard to get, as any upfront payment could be used by Anavex fund the ph2-3, which, Biogen could want a piece of this early. Being its an affordable trial, Anavex is playing hard ball as well and i believe to be in the drivers seat, getting cash from lpc to prove they do not need Biogen upfront cash to fund other trials. Sorry for the rambling here. Hopefully I made a point or 2. Obviously a lot of speculation, I know some hate speculation, so please ignore my post if you handle speculation!
